nigakinone profile

nigakinone: an NSAID that may be useful in treating ulcerative colitis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5320161
CHEMBL ID	1594741
CHEBI ID	81365
SCHEMBL ID	5664418
MeSH ID	M0534147

Synonym
MLS000574953
smr001215932
4-methoxy-5-hydroxycanthin-6-one
nigakinone
C17879
18110-86-6
HMS2269C08
unii-j7e73434d2
J7E73434D2 ,
5-hydroxy-4-methoxycanthin-6-one
6h-indolo(3,2,1-de)(1,5)naphthyridin-6-one, 5-hydroxy-4-methoxy-
CHEBI:81365 ,
SCHEMBL5664418
CHEMBL1594741
AC-34395
5-hydroxy-4-methoxy-6h-indolo[3,2,1-de][1,5]naphthyridin-6-one
PGFKZUOYIFDMQJ-UHFFFAOYSA-N
HY-N2128
CS-0018679
4-methoxy-1,6-diazatetracyclo[7.6.1.0^{5,16.0^{10,15]hexadeca-4,7,9(16),10,12,14-hexaene-2,3-dione
Q27155302
FT-0701509
3-hydroxy-4-methoxy-1,6-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-3,5(16),6,8,10,12,14-heptaen-2-one
MS-23755
6h-indolo[3,2,1-de][1,5]naphthyridin-6-one, 5-hydroxy-4-methoxy-
E80697

Excerpt	Reference	Relevance
"Nigakinone has potential therapeutic effects on colitis."	( Nigakinone alleviates DSS-induced experimental colitis via regulating bile acid profile and FXR/NLRP3 signaling pathways. Lin, C; Liu, F; Wang, M; Wang, Q; Yao, Y; Zhang, F; Zhu, C, 2023)	3.07

Excerpt	Reference	Relevance
"Dysfunction of copper homeostasis can lead to a host of disorders, which might be toxic sometimes."	( In vivo toxic effects of 4-methoxy-5-hydroxy-canthin-6-one in zebrafish embryos via copper dyshomeostasis and oxidative stress. Feng, F; Gong, G; He, MF; Jiang, L; Lin, Q; Liu, W; Qu, W; Xie, N; Zhang, J, 2018)	0.48

Excerpt	Reference	Relevance
"The pharmacokinetic results showed that the prototype of PQ-A was the main existing form in both physiological and pathological conditions."	( A comparative study on pharmacokinetics and tissue distribution of 5-hydroxy-4-methoxycanthin-6-one and its metabolite in normal and dextran sodium sulfate-induced colitis rats by HPLC-MS/MS. Lin, C; Liu, C; Liu, F; Wang, M; Yao, Y; Zhang, Q; Zhu, C, 2020)	0.56

Class	Description
beta-carbolines	Any pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	79.4328	0.6310	35.7641	100.0000	AID504339
USP1 protein, partial	Homo sapiens (human)	Potency	39.8107	0.0316	37.5844	354.8130	AID743255
GLS protein	Homo sapiens (human)	Potency	35.4813	0.3548	7.9355	39.8107	AID624170
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	3.9811	0.1000	22.9075	100.0000	AID485364
Smad3	Homo sapiens (human)	Potency	31.6228	0.0052	7.8098	29.0929	AID588855
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	3.5481	0.0355	20.9770	89.1251	AID504332
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	27.0050	5.8048	36.1306	65.1308	AID540253; AID540263
flap endonuclease 1	Homo sapiens (human)	Potency	11.2202	0.1337	25.4129	89.1251	AID588795
snurportin-1	Homo sapiens (human)	Potency	27.0050	5.8048	36.1306	65.1308	AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	31.6228	5.8048	16.9962	25.9290	AID540253
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	22.2775	0.0501	27.0736	89.1251	AID588590; AID720496
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	35.4813	1.9953	25.5327	50.1187	AID624288
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	1.1220	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1320174	Cerebral protective activity in anesthetized cerebral ischemia-induced Mongolian gerbil hippocampus assessed as protective values on density of surviving neurons in CA1 subfields of hippocampus at 100 mg/kg, po pretreated for 30 mins followed by bilateral	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	Evaluation of canthinone alkaloids as cerebral protective agents.
AID1194597	Inhibition of PTP1B (unknown origin) assessed as inhibition rate at 100 uM	2015	Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9	Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors.
AID1320173	Cerebral protective activity in cerebral ischemia-induced Mongolian gerbil assessed as passive avoidance test value at 100 mg/kg, po pretreated for 30 mins followed by bilateral ligation-induced ischemia for 5 mins measured on day 1 post 3 days ischemia i	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	Evaluation of canthinone alkaloids as cerebral protective agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (14.29)	29.6817
2010's	7 (50.00)	24.3611
2020's	5 (35.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.05	1
1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: precursor of mutagenic nitroso cpd in soy sauce; structure given in first source	2.11	1	harmala alkaloid
canthin-6-one canthin-6-one: from Zanthoxylum usambarense; structure in first source. canthin-6-one : An indole alkaloid that is 6H-indolo[3,2,1-de][1,5]naphthyridine substituted by an oxo group at position 6.	2.57	2	enone; indole alkaloid; organic heterotetracyclic compound	antimycobacterial drug; metabolite
1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: structure given in first source; RN given refers to cpd without isomeric designation. 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid : A member of the class of beta-carbolines that is 1,2,3,4-tetrahydro-beta-carboline substituted at position 3 by a carboxy group.	2.11	1	alpha-amino acid; aromatic amino acid; beta-carboline alkaloid	human urinary metabolite; human xenobiotic metabolite; plant metabolite; rat metabolite
vinpocetine [no description available]	2.13	1
beta-carboline-3-carboxylic acid methyl ester beta-carboline-3-carboxylic acid methyl ester: structure given in first source	2.11	1	beta-carbolines
5-methoxycanthin-6-one 5-methoxycanthin-6-one: isolated from Zanthoxylum chiloperone; structure in first source	2.11	1	alkaloid; organic heterotetracyclic compound
Amalorin [no description available]	2.11	1	alkaloid; organic heterotetracyclic compound
Methyl nigakinone 4,5-dimethoxycanthin-6-one: an active metabolite of Picrasma quassiodes; structure in first source	2.52	2	beta-carbolines
1-acetyl-beta-carboline 1-acetyl-beta-carboline: structure in first source	2.11	1	harmala alkaloid	metabolite
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.11	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
dehydrocrenatidine dehydrocrenatidine: a janus kinase inhibitor; structure in first source	2.11	1
1-Ethyl-9H-pyrido[3,4-b]indole [no description available]	2.11	1	harmala alkaloid
beta-carboline-1-propionic acid [no description available]	2.11	1	harmala alkaloid
1-methyl-beta-carboline-3-carboxylic acid 1-methyl-beta-carboline-3-carboxylic acid: metabolite from cows fed with corn silage; structure in first source	2.11	1
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.05	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
9-methoxycanthin-6-one 9-methoxycanthin-6-one: from roots of Eurycoma longifolia (Simaroubaceae). 9-methoxycanthin-6-one : An indole alkaloid that is the 9-methoxy derivative of canthin-6-one. Isolated from Eurycoma longifolia and Simaba multiflora, it exhibits cytotoxic activity towards human cancer cell lines.	2.11	1	aromatic ether; indole alkaloid; organic heterotetracyclic compound	antineoplastic agent; antiplasmodial drug; metabolite
rk 682 [no description available]	2.11	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.54	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.54	2
Cerebral Ischemia [description not available]	2.13	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.13	1
Colitis Gravis [description not available]	2.53	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.85	3
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	7.76	2
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.53	2
Polyarthritis [description not available]	2.08	1
Anasarca [description not available]	2.08	1
Arthritis Acute or chronic inflammation of JOINTS.	2.08	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.08	1

nigakinone

Description

Cross-References

Synonyms (26)

Research Excerpts

Effects

Toxicity

Pharmacokinetics

Drug Classes (1)

Protein Targets (13)

Potency Measurements

Biological Processes (23)

Molecular Functions (12)

Ceullar Components (10)

Bioassays (19)

Research

Studies (14)

Market Indicators

Research Demand Index: 11.94

Study Types

nigakinone

Description

Cross-References

Synonyms (26)

Research Excerpts

Effects

Toxicity

Pharmacokinetics

Drug Classes (1)

Protein Targets (13)

Potency Measurements

Biological Processes (23)

Molecular Functions (12)

Ceullar Components (10)

Bioassays (19)

Research

Studies (14)

Market Indicators

Research Demand Index: 11.94

Study Types

Related Drugs (18)

Related Conditions (12)